170 related articles for article (PubMed ID: 21842244)
1. Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer.
Wheeler SB; Carpenter WR; Peppercorn J; Schenck AP; Weinberger M; Biddle AK
Breast Cancer Res Treat; 2012 Jan; 131(1):207-16. PubMed ID: 21842244
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
[TBL] [Abstract][Full Text] [Related]
3. Delayed initiation of adjuvant chemotherapy in older women with breast cancer.
Smith-Graziani D; Lei X; Giordano SH; Zhao H; Karuturi M; Chavez-MacGregor M
Cancer Med; 2020 Oct; 9(19):6961-6971. PubMed ID: 32767723
[TBL] [Abstract][Full Text] [Related]
4. Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
Chu QD; Zhou M; Medeiros KL; Peddi P; Wu XC
Anticancer Res; 2017 Oct; 37(10):5585-5594. PubMed ID: 28982874
[TBL] [Abstract][Full Text] [Related]
5. Can differences in breast cancer utilities explain disparities in breast cancer care?
Schleinitz MD; DePalo D; Blume J; Stein M
J Gen Intern Med; 2006 Dec; 21(12):1253-60. PubMed ID: 16961753
[TBL] [Abstract][Full Text] [Related]
6. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
7. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
[TBL] [Abstract][Full Text] [Related]
8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
9. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
10. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer.
Bhargava A; Du XL
Cancer; 2009 Jul; 115(13):2999-3008. PubMed ID: 19452539
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy and differential invasive breast cancer specific survival in elderly women.
Kaplan HG; Malmgren JA; Atwood MK
J Geriatr Oncol; 2013 Apr; 4(2):148-56. PubMed ID: 24071540
[TBL] [Abstract][Full Text] [Related]
12. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
13. Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.
Henderson J; Adams P; Barber K
Clin Breast Cancer; 2019 Jun; 19(3):e475-e480. PubMed ID: 30852142
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis.
Gao HF; Li WP; Zhu T; Yang CQ; Yang M; Zhang LL; Ji F; Cheng MY; Li JQ; Wang K
Breast; 2020 Dec; 54():79-87. PubMed ID: 32947149
[TBL] [Abstract][Full Text] [Related]
16. A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer.
Nagel G; Röhrig B; Hoyer H; Wedding U; Katenkamp D
J Cancer Res Clin Oncol; 2003 Mar; 129(3):183-91. PubMed ID: 12709795
[TBL] [Abstract][Full Text] [Related]
17. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database.
Buszek SM; Lin HY; Bedrosian I; Tamirisa N; Babiera GV; Shen Y; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):795-802. PubMed ID: 31377160
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
19. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
DeMichele A; Putt M; Zhang Y; Glick JH; Norman S
Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466
[TBL] [Abstract][Full Text] [Related]
20. Acceptance of adjuvant chemotherapy recommendations in early-stage hormone-positive breast cancer.
Marcinkowski EF; Ottesen R; Niland J; Vito C
J Surg Res; 2017 Jun; 214():79-85. PubMed ID: 28624063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
